Clik here to view.
Comparing China’s Rising Contenders in Formulation and Delivery
Formulation and delivery (F/D) is one of the main pillars of the biopharmaceutical industry, and as a science and technology, is becoming increasingly strategic and important to drug development...
View ArticleClik here to view.
Liposomes Show Value in Delivering Diverse Molecules
Liposomal encapsulation is undeniably one of the more accepted, studied, and proven methods to increase efficacy of poorly-bioavailable drugs. In fact, its use has been so affirmed that it is now...
View ArticleClik here to view.
Article 3
Seeing the rapid growth in China’s insulin market, Sanofi, Novo Nordisk, and Lilly have been squaring off for a big insulin fight. On June 13h, Eli Lilly announced that its second insulin production...
View ArticleClik here to view.
Opportunities Arise in Alternative Delivery for Non-Device-Enabled...
The drug industry is facing an unprecedented level of challenges, threatening to crumble even the largest of players. Oral deliveries remain the dominant mode of drug delivery. But with a flagging...
View ArticleClik here to view.
Rolling in the Dough: Formulation and Delivery Developers Continue to Attract...
Formulation and delivery continues to hold strong in early 2013. Despite our previous doubts over the viability of RNA-based therapeutics due to difficulties associated with delivery, and several big...
View ArticleClik here to view.
Technology Can Ease the Pain for Individuals and Multinationals Alike
With all of the billion-dollar or even high-multimillion-dollar pain products such as Purdue’s Oxycontin, Pfizer’s Lyrica, Endo’s Lidoderm, and Janssen’s Duragesic already off-patent or going...
View ArticleClik here to view.
Heated Competition Towards Oral Insulin Presses On
Insulin administration has progressed significantly from a syringe and needle to the current use of insulin pens, which confers a much-needed convenience and ease of use. Nevertheless, for patients,...
View ArticleClik here to view.
Samsung, Apple, Nokia, HP, and Now Blackberry: A Month of Meh for Innovation...
Technology company buyouts are usually triumphant moments of validation, but this week’s announcement that Blackberry is considering a $4.7 billion offer actually shows how far the company has fallen....
View ArticleClik here to view.
Transdermals and Parenterals Dominate the Last Decade’s $7B of Formulation...
Formulation and delivery technologies have long been considered merely part of the product manufacturing process, with little need for innovation compared to new active ingredients. However, faced with...
View Article
